PCOS: Root Causes Beyond Insulin Resistance

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting an estimated 8–13% of women globally. It is defined by the Rotterdam criteria, requiring two of three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound.

The dominant clinical narrative frames PCOS primarily as an insulin resistance disorder — and insulin resistance is indeed a central driver in the majority of cases. But PCOS is a heterogeneous syndrome with multiple distinct phenotypes and root cause mechanisms. Reducing it to a single metabolic explanation misses the significant proportion of lean women with PCOS, the neuroendocrine drivers, the inflammatory mechanisms, and the adrenal contributions that require entirely different therapeutic approaches.

This article maps the full root cause landscape of PCOS.

PCOS Phenotypes: Not One Disease

The Rotterdam criteria define four PCOS phenotypes based on which combination of features is present:

• Phenotype A (Classic): hyperandrogenism + anovulation + polycystic ovaries — the most severe metabolic phenotype, highest insulin resistance
• Phenotype B: hyperandrogenism + anovulation (no polycystic morphology) — similar metabolic risk to Phenotype A
• Phenotype C (Ovulatory PCOS): hyperandrogenism + polycystic ovaries (ovulation preserved) — milder metabolic profile
• Phenotype D (Non-androgenic): anovulation + polycystic ovaries (no hyperandrogenism) — least metabolic risk; most controversial phenotype

Phenotype determines prognosis, metabolic risk, and optimal treatment strategy. A lean woman with Phenotype D has a fundamentally different root cause profile than an overweight woman with Phenotype A.

Root Cause 1: Insulin Resistance and Hyperinsulinemia

Insulin resistance is present in approximately 70% of women with PCOS — including 30–40% of lean women with PCOS. It is the dominant driver in classic PCOS and operates through several mechanisms:

• Ovarian insulin receptor hypersensitivity: while peripheral tissues (muscle, fat) are insulin resistant, ovarian theca cells retain insulin sensitivity. Hyperinsulinemia drives excess androgen production (testosterone, androstenedione) from theca cells via stimulation of CYP17A1 (the rate-limiting enzyme in androgen synthesis).
• SHBG suppression: insulin suppresses hepatic SHBG production, increasing free testosterone bioavailability and amplifying androgenic effects
• LH amplification: insulin potentiates LH-stimulated androgen production in theca cells, compounding the hyperandrogenic effect
• IGF-1 synergy: insulin resistance elevates IGF-1, which further stimulates ovarian androgen production

The result: a self-reinforcing cycle in which hyperinsulinemia drives hyperandrogenism, which impairs follicular development and ovulation, which perpetuates anovulation and the hormonal environment that sustains insulin resistance.

Root Cause 2: Neuroendocrine Dysregulation — The GnRH Pulse Generator

A neuroendocrine abnormality in GnRH pulsatility is present in the majority of women with PCOS and may be the primary upstream driver — particularly in lean PCOS.

• Accelerated GnRH pulse frequency: women with PCOS have faster GnRH pulse frequency than normal. This preferentially stimulates LH secretion over FSH secretion from the pituitary.
• Elevated LH:FSH ratio: high LH drives excess theca cell androgen production; relatively low FSH impairs follicular maturation and granulosa cell aromatase activity (which converts androgens to estrogens), leaving androgens to accumulate
• Progesterone resistance at the hypothalamus: normally, progesterone slows GnRH pulse frequency during the luteal phase. In PCOS, the hypothalamus is resistant to progesterone's slowing effect, perpetuating the fast pulse rate and high LH:FSH ratio — even in the absence of insulin resistance
• Kisspeptin dysregulation: kisspeptin neurons are the primary regulators of GnRH pulsatility. Androgen excess (from any cause) upregulates kisspeptin signaling, accelerating GnRH pulses and creating a feed-forward loop

This neuroendocrine mechanism explains why lean women with PCOS — who may have normal insulin sensitivity — still have elevated LH, suppressed FSH, and anovulation.

Root Cause 3: Adrenal Androgen Excess (Adrenal PCOS)

In approximately 20–30% of women with PCOS, the primary source of androgen excess is the adrenal glands rather than the ovaries. This is identified by elevated DHEA-S (the adrenal androgen marker) with normal or mildly elevated ovarian androgens.

• Adrenal CYP17A1 hyperactivity: the same enzyme that drives ovarian androgen excess can be overactive in the adrenal cortex, producing excess DHEA and androstenedione
• HPA axis dysregulation: chronic stress and cortisol dysregulation can drive adrenal androgen overproduction; ACTH stimulates both cortisol and adrenal androgen synthesis
• Exaggerated adrenarche: some women with adrenal PCOS have a history of premature adrenarche (early pubic hair development), suggesting a constitutional adrenal androgen excess pattern

Adrenal PCOS responds poorly to insulin-sensitizing interventions and requires HPA axis support, stress management, and sometimes low-dose corticosteroid therapy to suppress adrenal androgen production.

Root Cause 4: Chronic Inflammation

Chronic low-grade inflammation is both a cause and consequence of PCOS, creating a self-reinforcing inflammatory-androgenic loop:

• Inflammatory cytokines (TNF-α, IL-6, IL-18, CRP) are elevated in women with PCOS independent of obesity
• Inflammation directly stimulates ovarian androgen production via NF-κB-mediated upregulation of CYP17A1
• Inflammation drives insulin resistance in peripheral tissues, compounding the metabolic phenotype
• Androgens themselves promote inflammatory signaling, creating a bidirectional loop

Sources of chronic inflammation in PCOS include gut dysbiosis, dietary inflammatory load (refined carbohydrates, seed oils, ultra-processed foods), adipose tissue-derived cytokines, and environmental toxin burden.

Root Cause 5: Gut Dysbiosis

Emerging research identifies gut microbiome dysbiosis as a significant contributor to PCOS pathophysiology:

• Women with PCOS have reduced microbial diversity and altered Firmicutes:Bacteroidetes ratios compared to controls
• Dysbiosis increases intestinal permeability (leaky gut), allowing lipopolysaccharide (LPS) from gram-negative bacteria to enter circulation — triggering systemic inflammation and insulin resistance
• The estrobolome (gut bacteria that metabolize estrogen) is altered in PCOS, affecting estrogen recirculation and the estrogen:androgen balance
• Short-chain fatty acid (SCFA) production is reduced in PCOS dysbiosis, impairing insulin sensitivity and gut barrier integrity

Root Cause 6: Thyroid Dysfunction

Thyroid dysfunction — particularly Hashimoto's thyroiditis — is significantly more prevalent in women with PCOS than in the general population, and the two conditions share autoimmune and inflammatory mechanisms:

• Hypothyroidism impairs ovulation by disrupting GnRH pulsatility and LH secretion
• Elevated TSH stimulates ovarian theca cells (TSH receptors are expressed in the ovary), potentially contributing to androgen production
• Hypothyroidism elevates prolactin (TRH stimulates prolactin), which further suppresses ovulation
• Thyroid autoimmunity shares genetic and immune pathways with PCOS

Thyroid screening (TSH, free T4, TPO antibodies) is essential in all women with PCOS.

Root Cause 7: Environmental Endocrine Disruptors

Prenatal and postnatal exposure to endocrine-disrupting chemicals (EDCs) is increasingly recognized as a contributor to PCOS development:

• BPA (Bisphenol A): serum BPA levels are significantly elevated in women with PCOS; BPA disrupts ovarian steroidogenesis and promotes insulin resistance
• Phthalates: anti-androgenic in some contexts but disruptive to ovarian function and associated with PCOS features
• Prenatal androgen exposure: daughters of women with PCOS have higher rates of PCOS, partly mediated by in utero androgen exposure programming the fetal hypothalamus toward the PCOS neuroendocrine phenotype

Diagnosis: A Comprehensive Root Cause Workup

Standard PCOS diagnosis (Rotterdam criteria) identifies the syndrome but not the root cause. A comprehensive workup includes:

• Androgens: total testosterone, free testosterone, DHEA-S, androstenedione — to distinguish ovarian vs. adrenal source
• LH:FSH ratio: elevated LH:FSH (>2:1) confirms neuroendocrine dysregulation
• Insulin and glucose: fasting insulin, fasting glucose, HOMA-IR, 2-hour glucose tolerance test — to quantify insulin resistance
• SHBG: low SHBG confirms insulin-driven free androgen excess
• Thyroid panel: TSH, free T4, TPO antibodies
• Inflammatory markers: hsCRP, IL-6
• DUTCH Complete: comprehensive steroid hormone and metabolite mapping
• Pelvic ultrasound: ovarian morphology (12+ follicles per ovary or ovarian volume >10 mL)

Integrative Protocols by Root Cause

Insulin Resistance PCOS

• Inositol (Myo-inositol + D-chiro-inositol, 40:1 ratio): insulin sensitizer with strong evidence in PCOS; improves ovulation rates, reduces androgens, and lowers fasting insulin. Dose: 2–4g myo-inositol + 50–100mg D-chiro-inositol daily.
• Berberine: comparable to metformin in insulin sensitization; 500 mg 2–3x/day with meals
• Low-glycemic, anti-inflammatory diet: reduces insulin load and inflammatory burden simultaneously
• Resistance training: the most effective lifestyle intervention for improving insulin sensitivity in PCOS
• Metformin: first-line pharmaceutical insulin sensitizer; consider when lifestyle and nutritional interventions are insufficient

Adrenal PCOS

• HPA axis support: sleep optimization, stress management, adaptogenic botanicals (Ashwagandha)
• Avoid excessive caloric restriction and overtraining (both activate HPA and drive adrenal androgen production)
• Low-dose corticosteroid therapy (dexamethasone 0.25–0.5 mg at bedtime) under physician supervision to suppress adrenal androgen production

Inflammatory PCOS

• Anti-inflammatory diet: eliminate refined carbohydrates, seed oils, and ultra-processed foods; emphasize omega-3s, polyphenols, and fiber
• Omega-3 fatty acids (EPA/DHA): 2–3g/day; reduce inflammatory cytokines and improve insulin sensitivity in PCOS
• Gut microbiome restoration: high-fiber diet, targeted probiotics, address dysbiosis and intestinal permeability
• N-acetylcysteine (NAC): antioxidant and anti-inflammatory; evidence for improving ovulation and reducing androgens in PCOS. Dose: 600 mg 2–3x/day.

Neuroendocrine PCOS

• Progesterone supplementation (cyclic bioidentical progesterone) to restore hypothalamic progesterone sensitivity and slow GnRH pulse frequency
• Vitex agnus-castus: may modulate LH secretion and support GnRH regulation
• Address hypothalamic amenorrhea contributors: restore caloric adequacy, reduce excessive exercise, manage psychological stress

Conclusion

PCOS is not a single disease with a single cause — it is a heterogeneous syndrome in which insulin resistance, neuroendocrine dysregulation, adrenal androgen excess, chronic inflammation, gut dysbiosis, thyroid dysfunction, and environmental exposures can each serve as primary or contributing root causes. Effective treatment requires phenotyping the individual patient, identifying the dominant root cause mechanisms, and applying targeted interventions accordingly.

The insulin-centric model of PCOS, while valid for the majority of classic phenotype patients, fails the lean woman with neuroendocrine PCOS, the woman with adrenal androgen excess, and the woman whose PCOS is driven primarily by inflammatory or thyroid mechanisms. A root cause framework ensures that every woman with PCOS receives a diagnosis — and a treatment plan — that reflects her actual biology.